Small molecular inhibitors for KRAS-mutant cancers

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Rat sarcoma (RAS) gene isoforms (KRAS, NRAS, HRAS) are frequently mutated in various cancers.
• RAS-mutant cancers exhibit high aggressiveness and poorer patient prognosis compared to non-RAS-mutant cancers.
• Despite historical challenges, recent advancements have yielded targeted therapies for specific RAS mutations.

Purpose of the Study:

• To review the progress and potential of small-molecule inhibitors targeting RAS-mutant cancers.
• To explore different therapeutic strategies, including direct RAS inhibitors and combination therapies.
• To highlight the impact of these inhibitors on improving patient outcomes.

Main Methods:

• Review of clinical trial data for small-molecule inhibitors targeting RAS.
• Analysis of therapeutic strategies including direct KRAS inhibitors, pan-RAS inhibitors, and effector pathway inhibitors.
• Examination of combination therapies involving immune checkpoint inhibitors and RAS inhibitors.

Main Results:

• Development of allele-specific covalent inhibitors, such as Sotorasib (AMG510), for KRAS-G12C mutant non-small-cell lung cancer.
• FDA approval of Sotorasib as a second-line treatment for specific NSCLC patients.
• Ongoing clinical trials for various RAS inhibitors and combination therapies show promising results.

Conclusions:

• Small-molecule inhibitors represent a significant breakthrough in treating previously undruggable RAS-mutant cancers.
• Targeted therapies and combination strategies hold great promise for improving the prognosis of patients with RAS-driven tumors.
• Continued research and clinical trials are essential to further advance RAS-targeted cancer therapy.